These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice. Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408 [TBL] [Abstract][Full Text] [Related]
3. Parity-induced mammary epithelial cells facilitate tumorigenesis in MMTV-neu transgenic mice. Henry MD; Triplett AA; Oh KB; Smith GH; Wagner KU Oncogene; 2004 Sep; 23(41):6980-5. PubMed ID: 15286714 [TBL] [Abstract][Full Text] [Related]
4. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice. Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559 [TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Blavier L; Lazaryev A; Dorey F; Shackleford GM; DeClerck YA Cancer Res; 2006 Mar; 66(5):2691-9. PubMed ID: 16510589 [TBL] [Abstract][Full Text] [Related]
7. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Ha HY; Moon HB; Nam MS; Lee JW; Ryoo ZY; Lee TH; Lee KK; So BJ; Sato H; Seiki M; Yu DY Cancer Res; 2001 Feb; 61(3):984-90. PubMed ID: 11221894 [TBL] [Abstract][Full Text] [Related]
9. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Zinser GM; Welsh J Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467 [TBL] [Abstract][Full Text] [Related]
10. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707 [TBL] [Abstract][Full Text] [Related]
11. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Jacquemart IC; Springs AE; Chen WY Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488 [TBL] [Abstract][Full Text] [Related]
12. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice. van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875 [TBL] [Abstract][Full Text] [Related]
13. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Gallahan D; Jhappan C; Robinson G; Hennighausen L; Sharp R; Kordon E; Callahan R; Merlino G; Smith GH Cancer Res; 1996 Apr; 56(8):1775-85. PubMed ID: 8620493 [TBL] [Abstract][Full Text] [Related]
14. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression. Corsino P; Davis B; Law M; Chytil A; Forrester E; Nørgaard P; Teoh N; Law B Cancer Res; 2007 Apr; 67(7):3135-44. PubMed ID: 17409420 [TBL] [Abstract][Full Text] [Related]
15. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Krane IM; Leder P Oncogene; 1996 Apr; 12(8):1781-8. PubMed ID: 8622899 [TBL] [Abstract][Full Text] [Related]
16. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu. Hewitt SC; Bocchinfuso WP; Zhai J; Harrell C; Koonce L; Clark J; Myers P; Korach KS Cancer Res; 2002 May; 62(10):2798-805. PubMed ID: 12019156 [TBL] [Abstract][Full Text] [Related]
17. Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development. Jolicoeur P; Bouchard L; Guimond A; Ste-Marie M; Hanna Z; Dievart A Biochem Soc Symp; 1998; 63():159-65. PubMed ID: 9513720 [TBL] [Abstract][Full Text] [Related]
18. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus. Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997 [TBL] [Abstract][Full Text] [Related]
19. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Witty JP; Lempka T; Coffey RJ; Matrisian LM Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342 [TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice. Elson A Oncogene; 1999 Dec; 18(52):7535-42. PubMed ID: 10602512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]